Drug Trial Radar · NCT06747923
SB17170 Phase 2 Trial in IPF Patients
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jan 27, 2025
Primary completion
Jul 21, 2026
Study completion Jul 28, 2026
Sponsor
- Lead sponsor
- SPARK BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
Conditions
- IPF
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
SB17170Drug
Taking SB17170 orally once a day
PlaceboDrug
Taking Placebo orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in FVC (ml)Time frame: Week 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Myong Ji Hospital
Goyang, South Korea
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong, South Korea
Seoul Asan Hospital
Seoul, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.